文献速递淋巴瘤

结外鼻型NK/T细胞淋巴瘤一线非蒽环类方案化疗:中国淋巴瘤协作组回顾性分析

First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG.
PubMed 文献 · Blood Adv · 2020-01-01

基于中国淋巴瘤协作组(CLCG)2000-2015年数据库,纳入2560例初诊结外鼻型NK/T细胞淋巴瘤患者,比较非蒽环类(non-ANT)与蒽环类(ANT)方案化疗的生存获益。非蒽环类方案显著改善生存,全队列5年OS为68.9%对57.5%,5年PFS为59.5%对44.5%,在各亚组及接受放疗的早期患者中优势一致,多因素和倾向性评分匹配(PSM)分析后仍显著。

要点

  • 全队列非蒽环类方案5年OS 68.9%、PFS 59.5%,均优于蒽环类方案的57.5%和44.5%。
  • 无论分期和风险分层亚组,非蒽环类方案临床优势均显著。
  • 接受放疗的早期患者中,非蒽环类方案生存获益仍显著。

核心结论

  • 非蒽环类方案较蒽环类方案显著改善结外鼻型NK/T细胞淋巴瘤患者生存,支持其作为一线治疗。

研究设计与样本

  • 回顾性分析中国淋巴瘤协作组(CLCG)数据库2000-2015年初诊患者2560例,接受化疗伴或不伴放疗。
  • 采用倾向性评分匹配(PSM)和多因素分析比较两组总生存(OS)和无进展生存(PFS)。

主要发现

  • 全队列5年OS:非蒽环类方案68.9% vs 蒽环类方案57.5%。
  • 全队列5年PFS:非蒽环类方案59.5% vs 蒽环类方案44.5%。
  • 非蒽环类方案在各分期和风险分层亚组中优势均显著,接受放疗的早期患者中仍显著。
  • 多因素和PSM分析校正后,非蒽环类方案生存获益一致。

关键数值与推荐

  • 全队列5年OS非蒽环类68.9% vs 蒽环类57.5%。
  • 全队列5年PFS非蒽环类59.5% vs 蒽环类44.5%。

临床怎么用

  • 原文结论认为这些发现为非蒽环类方案作为结外鼻型NK/T细胞淋巴瘤一线治疗提供了额外证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The present study investigated the survival benefit of non-anthracycline (ANT)-based vs ANT-based regimens in a large-scale, real-world cohort of patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTCL). Within the China Lymphoma Collaborative Group (CLCG) database (2000-2015), we identified 2560 newly diagnosed patients who received chemotherapy with or without radiotherapy. Propensity score matching (PSM) and multivariable analyses were used to compare overall survival (OS) and progression-free survival (PFS) between the 2 chemotherapy regimens. We explored the survival benefit of non-ANT-based regimens in patients with different treatments in early-stage disease and in risk-stratified subgroups. Non-ANT-based regimens significantly improved survivals compared with ANT-based regimens. The 5-year OS and PFS were 68.9% and 59.5% for non-ANT-based regimens compared with 57.5% and 44.5% for ANT-based regimens in the entire cohort. The clinical advantage of non-ANT-based regimens was substantial across the subgroups examined, regardless of stage and risk-stratified subgroup, and remained significant in early-stage patients who received radiotherapy. The survival benefits of non-ANT-based regimens were consistent after adjustment using multivariable and PSM analyses. These findings provide additional evidence supporting non-ANT-based regimens as a first-line treatment of patients with ENKTCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Qi SN, Yang Y, Song YQ, et al. First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. Blood Adv. 2020. PMID: 32658985. doi:10.1182/bloodadvances.2020001852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。